Showing results (61-70 of 170) with videos related to

Sort By:
Pageof 17
Journal of Clinical Medicine|March 6, 2020
miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In VitroMarkus Krebs, Antonio Giovanni Solimando, Charis Kalogirou, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 5, 2022
Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratioSebastian Zimmermann, Fatemeh Aghai, Bastian Schilling, et al.
Cancer Medicine|June 18, 2014
Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort studyElisabeth Livingstone, Loes M Hollestein, Myrthe P P van Herk-Sukel, et al.
Journal for Immunotherapy of Cancer|September 24, 2025
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitisKim Nikola Oliva, Lisa Arnold, Lucie Heinzerling, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2019
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaSophia Kreft, Anja Gesierich, Thomas Eigentler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2013
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cellsBenjamin Weide, Alexander Martens, Henning Zelba, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2019
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskTitus J Brinker, Achim Hekler, Alexander H Enk, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 25, 2023
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinibSebastian Zimmermann, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, et al.
Pageof 17